Project Grant R44AG046025

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...

This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $506,061 to Redwood Neuro Inc. to develop an innovative blood-based diagnostic platform called SIMOLISA. The goal is to revolutionize Alzheimer's disease (AD) diagnostics by enabling ultra-sensitive and affordable detection of critical AD biomarkers such as p-tau proteins and β-amyloid. Unlike current high-cost systems, SIMOLISA utilizes cost-effective materials and...

The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $426,555 project grant to Duke University to develop a novel molecular diagnostic technology called "Cascade Amplification by Recycling Trigger Probe" (CARTP) for rapid, multiplex, and ultra-sensitive detection of circulating microRNA (miRNA) biomarkers in clinical plasma samples for the early detection of Alzheimer's disease (AD). The project aims to address the technical...

The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

The National Institute on Aging (NIA) awarded a $483,346 Project Grant to Meganano Diagnostics Inc. under the Aging Research Federal Grant Program (CFDA 93.866) for the development of an RT-qPCR assay for early diagnosis of Alzheimer's disease (AD). The project aims to leverage changes in T cell receptor (TCR) clonality in peripheral blood mononuclear cells (PBMCs) as a potential biomarker for early AD detection. Preliminary research by Meganano Diagnostics has demonstrated increased TCR...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This $306,509 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Captis Diagnostics Inc. aims to develop a technology platform for rapid magnetic isolation of neuronal extracellular vesicles (EVs) from blood plasma samples. The goal is to enable the detection of biomarkers for neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury through a minimally invasive liquid biopsy approach. Key activities include developing...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Tauvision, Inc. provides $493,384 to develop an eyedrop-based, non-invasive diagnostic test for Alzheimer's disease. The project aims to optimize a fluorescent compound that can label pathological protein aggregates in the eye and be imaged using standard ophthalmology equipment, allowing for a direct measurement of central nervous system biomarkers. In Phase 1, the researchers will improve the...